You just read:

Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Therapy

News provided by

Audentes Therapeutics, Inc.

May 01, 2019, 14:15 ET